Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma

M. Shirin Sabbaghian, Gary Rothberger, Alexandra P. Alongi, Jean Pierre Gagner, Judith D. Goldberg, Linda Rolnitzky, Luis Chiriboga, Cristina H. Hajdu, David Zagzag, Ross Basch, Peter Shamamian

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Aim: To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique. Results: Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls. Conclusion: Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.

Original languageEnglish (US)
Pages (from-to)2911-2917
Number of pages7
JournalAnticancer Research
Volume30
Issue number7
StatePublished - Jul 2010
Externally publishedYes

Fingerprint

Adenocarcinoma
Endothelial Cells
Intercellular Signaling Peptides and Proteins
Neoplasms
Vascular Endothelial Growth Factor A
Exocrine Pancreas
Tumor Biomarkers
Pancreatic Neoplasms
Flow Cytometry
Biomarkers
Enzyme-Linked Immunosorbent Assay
Immunohistochemistry
Recurrence

Keywords

  • Angiogenesis
  • Endothelial cells
  • Neovascularization
  • Pancreatic cancer
  • Placental growth factor

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Sabbaghian, M. S., Rothberger, G., Alongi, A. P., Gagner, J. P., Goldberg, J. D., Rolnitzky, L., ... Shamamian, P. (2010). Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Research, 30(7), 2911-2917.

Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. / Sabbaghian, M. Shirin; Rothberger, Gary; Alongi, Alexandra P.; Gagner, Jean Pierre; Goldberg, Judith D.; Rolnitzky, Linda; Chiriboga, Luis; Hajdu, Cristina H.; Zagzag, David; Basch, Ross; Shamamian, Peter.

In: Anticancer Research, Vol. 30, No. 7, 07.2010, p. 2911-2917.

Research output: Contribution to journalArticle

Sabbaghian, MS, Rothberger, G, Alongi, AP, Gagner, JP, Goldberg, JD, Rolnitzky, L, Chiriboga, L, Hajdu, CH, Zagzag, D, Basch, R & Shamamian, P 2010, 'Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma', Anticancer Research, vol. 30, no. 7, pp. 2911-2917.
Sabbaghian MS, Rothberger G, Alongi AP, Gagner JP, Goldberg JD, Rolnitzky L et al. Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. Anticancer Research. 2010 Jul;30(7):2911-2917.
Sabbaghian, M. Shirin ; Rothberger, Gary ; Alongi, Alexandra P. ; Gagner, Jean Pierre ; Goldberg, Judith D. ; Rolnitzky, Linda ; Chiriboga, Luis ; Hajdu, Cristina H. ; Zagzag, David ; Basch, Ross ; Shamamian, Peter. / Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma. In: Anticancer Research. 2010 ; Vol. 30, No. 7. pp. 2911-2917.
@article{a63ebebc94584f6e890bb1ecac83e97e,
title = "Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma",
abstract = "Aim: To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique. Results: Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls. Conclusion: Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.",
keywords = "Angiogenesis, Endothelial cells, Neovascularization, Pancreatic cancer, Placental growth factor",
author = "Sabbaghian, {M. Shirin} and Gary Rothberger and Alongi, {Alexandra P.} and Gagner, {Jean Pierre} and Goldberg, {Judith D.} and Linda Rolnitzky and Luis Chiriboga and Hajdu, {Cristina H.} and David Zagzag and Ross Basch and Peter Shamamian",
year = "2010",
month = "7",
language = "English (US)",
volume = "30",
pages = "2911--2917",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "7",

}

TY - JOUR

T1 - Levels of elevated circulating endothelial cell decline after tumor resection in patients with pancreatic ductal adenocarcinoma

AU - Sabbaghian, M. Shirin

AU - Rothberger, Gary

AU - Alongi, Alexandra P.

AU - Gagner, Jean Pierre

AU - Goldberg, Judith D.

AU - Rolnitzky, Linda

AU - Chiriboga, Luis

AU - Hajdu, Cristina H.

AU - Zagzag, David

AU - Basch, Ross

AU - Shamamian, Peter

PY - 2010/7

Y1 - 2010/7

N2 - Aim: To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique. Results: Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls. Conclusion: Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.

AB - Aim: To evaluate circulating endothelial lineage cells (ELCs) as biomarkers of tumor neovascularization in patients with pancreatic ductal adenocarcinoma (PDAC). Materials and Methods: ELCs were isolated from the peripheral blood of patients with PDAC (n=14) or controls (n=17) before and after tumor resection/surgery and quantified using flow cytometry. Vascular endothelial growth factor (VEGF) and placental growth factor (PlGF) were detected in tumor using immunohistochemistry and in plasma using an ELISA technique. Results: Circulating ELC levels were increased in patients with PDAC compared to controls. After PDAC resection, ELC levels declined. ELC level increases were associated with cancer recurrence. VEGF and PlGF were identified in cancer cells and exocrine pancreas cells. Only PlGF was detected in tumor-associated inflammatory cells. Plasma levels of PlGF were higher in patients with PDAC compared to controls. Conclusion: Circulating ELCs are a potential biomarker of PDAC neovascularization, and PlGF may be an important target in treatment of PDAC.

KW - Angiogenesis

KW - Endothelial cells

KW - Neovascularization

KW - Pancreatic cancer

KW - Placental growth factor

UR - http://www.scopus.com/inward/record.url?scp=77955783268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955783268&partnerID=8YFLogxK

M3 - Article

C2 - 20683032

AN - SCOPUS:77955783268

VL - 30

SP - 2911

EP - 2917

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 7

ER -